FDA Clearance Tracker · K193167
NxTAG Respiratory Pathogen Panel, NxTAG Respiratory Pathogen Panel Files, SYNCT Software
Last checked: Nov 19, 2026Latest source record: Dec 11, 2019 (this decision)Source: openFDAMethods & limitations
Decided
Dec 11, 2019
Substantially Equivalent
Time to decision
26 days
Received Nov 15, 2019. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Special
Device class
Class II
The decision
- FDA number
- K193167
- Device name
- NxTAG Respiratory Pathogen Panel, NxTAG Respiratory Pathogen Panel Files, SYNCT Software
- Applicant
- Luminex Molecular Diagnostics, Inc.
- Applicant location
- Toronto, CA
- Received
- Nov 15, 2019
- Decided
- Dec 11, 2019
- Decision
- Substantially Equivalent
- Submission type
- Special
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.3980
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code OCC. The earliest in FDA's data is DEN070013, decided Jan 3, 2008.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K193167
- The applicant filed a statement instead of a public summary, or the summary is not at FDA's usual address. Check the FDA record.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Luminex Molecular Diagnostics, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K242613 · Decided Oct 2, 2024 · 29 days after receipt
Device type: Respiratory Virus Panel Nucleic Acid Assay System (OCC) · Laboratory Medicine & Pathology
K231758 · Decided Mar 11, 2024 · 269 days after receipt
Device type: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents (QOF) · Laboratory Medicine & Pathology
K191161 · Decided Nov 12, 2019 · 195 days after receipt
Device type: Gastrointestinal Pathogen Panel Multiplex Nucleic Acid-Based Assay System (PCH) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.